Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esketamine + pregabalin
- Development stage
- Phase 3
- Lead developer
- OMJ Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of esketamine and pregabalin used for pain management. Esketamine is an NMDA receptor antagonist while pregabalin acts on calcium channels to reduce pain signals. The combination shows synergistic analgesic effects, particularly effective for acute postsurgical pain management with reduced opioid requirements. Clinical studies demonstrate significant reduction in moderate-to-severe pain after spinal surgery and other procedures compared to either drug alone or placebo.
- Other names
- s-ketamine + pregabalin
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on esketamine + pregabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esketamine + pregabalin.